Clinical Trials

The Michigan Medicine Department of Radiation Oncology is a worldwide leader in cancer treatment and research. The novel research studies and clinical trials conducted by our faculty drives discovery and advances our cancer treatment delivery and effectiveness.

To learn more about the studies in Radiation Oncology listed below, please email Jody Sharp or phone 734-615-4909. 

Questions about cancer treatment at Michigan Medicine can also be addressed at the Rogel Cancer Center AnswerLine: (800) 865-1125. To learn more about open clinical trials throughout the Michigan Medicine enterprise, search the Rogel Cancer Center's clinical trials directory. For Oncology-specific trials, go to the Rogel Cancer Center's Oncology Clinical Trials listing.


Changing the way oropharyngeal cancer is treated
A trial published in 2010 showed that intensity-modulated chemoradiotherapy can be delivered in such a way as to minimize swallowing difficulty in patients being treated for oropharyngeal cancer. The trial found that this way of delivering therapy did not diminish the effectiveness the treatment. This way of delivering therapy has now become standard practice for treatment of this type of cancer.


Changing the way hepatocellular cancer is treated
Our physicians showed in a 2005 trial that hepatocellular cancer can be effectively treated with radiation. Using techniques for dose planning and conformal therapy that were new at the time, our clinicians were able to give high doses of radiation to the tumor which resulted in increased survival.  Building on this trial, our physicians and others have continued to improve and refine the treatment of hepatocellular cancer with radiation.


List of Trials


RTOG 1119: Phase II Randomized study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in combination with concurrent Lapatinib in patients with Brain metastasis from HER-2 positive breast cancer

NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer


UMCC 2012.006: Phase II Study of High Dose Radiotherapy and Concurrent Temozolomide Using Biologically-Based Target Volume Definition in Patients with Newly Diagnosed Glioblastoma

RTOG 1071 / ALLIANCE N0577: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (Alliance N0577)

NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

NRG-BN003: Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Head & Neck

UMCC 2017.113: A Phase II Trial of Individualized Adaptive De-Escalated Radiotherapy Using Pre- and Mid-Treatment FDG-PET/CT for HPV-Related Oropharynx Cancer

UMCC 2013.062: Randomized Phase II study of DCE-MRI-based dose escalation for poor-prognosis head and neck cancer

NRG-HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)


(none open at this time)


UMCC 2015.035: A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (R-DART)


NRG-G1002: A Phase I Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

UMCC 2015.039: A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma

UMCC 2003.081: Assessment of Liver Function in Patients Undergoing Hepatic Irradiation

UMCC 2006.067: A Pilot Study of Radiation Toxicity Using MRI-Based Perfusion.

HUM00133653: A Study of Circulating Biomarkers in Hepatocellular Carcinoma

HUM00085016: A Study of Circulating Tumor Cells and Exosomes in Patients Treated with Chemoradiation for Adenocarcinoma of the Pancreas


NRG-GU006A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer

UMCC 2017.156: Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apalutamide

NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer

UMCC 2014.142: Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy

UMCC 2016.072: ARN-509 + Abiraterone acetate + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study

RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

NRG-GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel


New NRG Study Coming Soon!


UMCC 2012.113: Optimization of MRI for Radiation Therapy

VA Trials

Kim 0005: Prospective Registry Trial of Patients with Focal Hypofractionated Image Guided Radiation Therapy For Brain Metastases at the VA Ann Arbor Healthcare System

Kim 0004: A Pilot Study of Circulating Tumor Cells in Patients Undergoing Definitive Radiation Therapy at the Veterans Affairs Ann Arbor Healthcare System

Shumway IRB-2015-300Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial (RTOG 0924)

Mierzwa IRB-2016-353Randomized Phase II Study of DCE-MRI Based Dose Escalation for Poor-Prognosis Head and Neck Cancer (UMCC 2013.062)

Mierzwa 0002: Prospective Registry Trial of Patients Treated with Stereotactic Body Radiotherapy for Recurrent or Second Primary Head and Neck Cancer at the VA Ann Arbor Healthcare System

Mierzwa 0003: Mitigation of Radiation Pneumonitis & Fibrosis (ACE inhibitor trial)

Mierzwa IRB-2016-351Observational Phase 2 trial of mid-treatment and early post-treatment PET-CT during definitive chemoradiation for Squamous cell carcinoma of the oropharynx at the AAVA (PET study)

Mierzwa IRB-2015-350A Pilot Study of Response-Driven Adaptive Radiation Therapy For Patients with Locally Advanced NSCLCa (UMCC 2015.035)